ERIC BJERKHOLT - 30 Nov 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role: Chief Financial Officer
Signature: /s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 30 Nov 2022
Net transactions value: -$128,602
Form type: 4
Filing time: 02 Dec 2022, 15:25:44 UTC
Previous filing: 03 Jun 2022
Next filing: 02 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KDNY	Common Stock	Options Exercise		+16,414	+74%		38,617	30 Nov 2022	Direct	F1
transaction	KDNY	Common Stock	Sale	$128,602	-5,770	-15%	$22.29	32,847	01 Dec 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KDNY	Restricted Stock Units	Options Exercise	$0	-16,414	-50%	$0.000000	16,415	30 Nov 2022	Common Stock	16,414		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSU") convert into common stock on a one-for-one basis.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	Each RSU represents a contingent right to receive one share of Issuer's common stock.
F4	The RSUs vested as to 33.33% of the total shares on November 30, 2021 and November 30, 2022, and thereafter vests as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date.